The FTSE 100’s still falling! Could this dividend stock help mend your stocks portfolio?

Royston Wild discusses a top FTSE 100 dividend share that might bounce back soon.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

These are stressful times to be a share investor. The FTSE 100 continues to dive and a fall below 6,500 points earlier took it to its lowest since summer 2016.

It’s true that those with a sound stock-buying strategy should have little to fear in the wider scheme of things. You should always look to load up with a view to holding companies for the long term, say a minimum of 10 years. If you’ve done your homework then, it’s likely that your equities will recover from the current rout and make you some big profits in the coming years.

Still, it’s quite disconcerting for someone to see their stocks portfolio smeared in red. With the global issues continuing, it’s difficult to predict when the haemorrhaging will stop. In times like this it may be a good idea to load up on classic defensive stocks.

The current washout is hammering all stocks, regardless of their risk profiles. But safe havens could be among the first to rise when market appetite tentatively begins to pick up.

A safe-haven sinker

Healthcare is a classic safe haven in times of social, political and economic crises like now. Consumer spending on a variety of goods and services might take a whack, but one thing we cannot do without is medicines.

I believe that buying shares in GlaxoSmithKline (LSE: GSK) could be a good idea following recent heavy selling. The Footsie firm’s fallen 15% in value since hitting 20-year highs in the middle of January. Some insipid full-year financials at the start of the month set the train in motion. And those fears over the COVID-19 crisis have worsened the rout.

At current prices though, Glaxo carries the sort of valuations that could tempt dip buyers before long. Its forward P/E ratio of 13.7 times certainly looks cheap. And a 5.1% dividend yield for 2020 looks juicy too. It beats the corresponding prospective average for the broader FTSE 100 by around one whole percentage point.

Bad news

As I say, those latest financials weren’t exactly top-drawer stuff. Glaxo said that total revenues rose 9% in the fourth quarter to £8.9bn and that adjusted operating profits tanked 16% to £1.9bn. The latter figure in particular was much weaker than the City had been expecting.

This wasn’t the worst of it. Glaxo warned that adjusted earnings per share would likely fall between 1% and 4% at constant exchange rates in 2020. This reflects a ramping-up of R&D costs as well as expectations of more currency-related headwinds.

A long-term lovely

The release was disappointing, sure. But is it a game-changer for Glaxo’s investment case? Certainly not, at least in my opinion.

There were certainly some positive nuggets of information in that latest statement that underlined the pharma play’s terrific long-term profits outlook. Sales of blockbuster new products like Shingrix continued to rip higher in the last quarter. There was exciting news on the pipeline too. Glaxo said that it expects regulatory approval on six products spanning the business in 2020. It is also expecting proof-of-concept readouts on what it deems “several key pipeline assets” in oncology and vaccines later this year.

Its share price might be on the defensive today. But I fully expect Glaxo to bounce back sooner rather than later.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »

Investing Articles

£12K in savings? Here’s how I could turn that into £13K annual passive income

This Fool explains how investing a lump sum can help her build a passive income stream to enjoy in her…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s why Rolls-Royce shares are now set to fly over the £4 mark

Once again, Rolls-Royce shares are crushing the FTSE 100. Should I add to my holding of this stock at the…

Read more »

Investing Articles

1 under the radar FTSE 100 AI stock investors should consider buying

Our writer explains why this FTSE 100 pick could be a shrewd investment with its established experience of using AI…

Read more »

Investing Articles

Does the beaten-down Diageo share price make it a no-brainer buy?

Harvey Jones spent years waiting for the Diageo share price to look like good value, before finally buying it in…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

8%+ yields! Should I buy these FTSE 100 income shares this month?

Christopher Ruane weighs some pros and cons of two FTSE 100 shares, both of which have a dividend yield over…

Read more »